Enabling Universal Access
to Gene Therapy
01
Current AAVs - The Gene Therapy Challenge
In over hundreds of clinical trials, viral vectors are used as a biological gene delivery system. Of these, Adeno-Associated Virus (AAV) is the most widely used vector system.
But current Cell-Based technology is unsuitable for the complexity of AAV development and production, resulting in low therapeutic product efficacy, high toxicity, slow development and costly production.
02
The Ultimate Solution for AAV Gene Therapy
At Fuse, we make AAVs outside the cell.
Our Fuse Technology, a cell-free AAV filling platform eliminates the need for traditional cell-based process, ensuring "100%" purity of AAV product in a single step.
Using our Fuse Technology, we have developed the superior alternative, by creating the Fuse Vectors
03
Delivering on the Promise of Gene Therapy
The combination of Fuse Technology and Optimization Engine aims to incentivize gene therapy development for all genetic illnesses and accelerate breakthroughs of better and safety therapies.
